Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases
- Authors: Lishchinskaya A.A.1, Knyazev O.V.1,2,3, Kagramanova A.V.1, Dudina G.A.1, Sabelnikova E.A.1, Li I.A.1, Noskova K.K.1, Bodunova N.A.1, Parfenov A.I.1
-
Affiliations:
- Loginov Moscow Clinical Scientific Center
- Ryzhykh National Medical Research Centre for Coloproctology
- Research Institute of Health Organization and Medical Management
- Issue: Vol 94, No 2 (2022)
- Pages: 172-179
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/105511
- DOI: https://doi.org/10.26442/00403660.2022.02.201367
- ID: 105511
Cite item
Full Text
Abstract
Background. Inflammatory bowel diseases (IBD) are characterized by chronic immune inflammation of the mucous membrane and/or the thickness of the intestinal wall, and are also accompanied by disorders of the blood clotting system and the development of a hypercoagulation state.
Aim. To identify the frequency of thromboembolic complications (TEC) in IBD patients and to determine the influence of acquired and inherited hypercoagulation factors that contribute to the development of TEС.
Materials and methods. The clinical status of 1,238 IBD patients who were treated in 2019 was evaluated. Of these, 748 patients with ulcerative colitis (UC) and 490 patients with Crohn's disease (CD). Among UC patients, there were 369 (49.3%) men and 379 (50.7%) women. In 10.1% of patients with UC, there were clinically significant feasibility studies. There were 227 (46.3%) men and 263 (53.7%) women among patients with CD; 7.3% of patients with CD had clinically significant feasibility studies.
Results. In general 112 (9.0%) of 1,238 IBD patients had clinically significant feasibility studies. Among patients with UC (n=748), 76 (10.2%) showed clinically significant feasibility studies. Among patients with CD (n=490), 36 (7.3%) had a feasibility study. Of 112 IBD patients with clinically significant TEC, 45 (40.2%) had genetic polymorphisms that increase affinity for fibrinogen, increase platelet aggregation, and contribute to a decrease in the activity of folate cycle enzymes, including methylenetetrahydrofolate reductase, which may be manifested by a moderate increase in homocysteine levels. Of the 45 IBD patients with clinically significant TEC due to inherited factors, 30 (66.6%) patients had UC, 15 (33.7%) patients had CD (hazard ratio 1.038, 95% confidence interval 0.746–1.444; χ2=0.049; p=0.83921); 67 (59.8%) patients with IBD who had clinically significant TEC did not have genetic polymorphisms leading to hypercoagulation.
Conclusion. Based on the analysis, we can conclude that such risk factors for the development of TEC as the status of a smoker, long bed rest, taking hormonal contraceptives, varicose veins of the lower extremities, high activity of the disease, glucocorticoids therapy, the extent of intestinal damage in patients with IBD, genetic factors, should be taken into account by gastroenterologists in the treatment of patients with UC and CD. The hereditary factor of hypercoagulation equally affects the development of TEC, both in patients with UC and CD.
Full Text
##article.viewOnOriginalSite##About the authors
Albina A. Lishchinskaya
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0001-7891-2702
канд. мед. наук, ст. науч. сотр. отд-ния воспалительных заболеваний кишечника
Russian Federation, MoscowOleg V. Knyazev
Loginov Moscow Clinical Scientific Center; Ryzhykh National Medical Research Centre for Coloproctology; Research Institute of Health Organization and Medical Management
Author for correspondence.
Email: oleg7@bk.ru
ORCID iD: 0000-0001-7250-0977
д-р мед. наук, зав. отд-нием воспалительных заболеваний кишечника; проф. научно-образовательного отд.; вед. специалист организационно-методического отд. по колопроктологии
Russian Federation, Moscow; Moscow; MoscowAnna V. Kagramanova
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0002-3818-6205
канд. мед. наук, ст. науч. сотр. отд-ния воспалительных заболеваний кишечника
Russian Federation, MoscowGalina A. Dudina
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0001-9673-1067
д-р мед. наук, зав. отд-нием гематологии
Russian Federation, MoscowElena A. Sabelnikova
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0001-7519-2041
д-р мед. наук, зам. дир. по науке
Russian Federation, MoscowIrina A. Li
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0002-9508-7502
д-р мед. наук, глав. врач
Russian Federation, MoscowKarina K. Noskova
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0001-5734-0995
канд. мед. наук, зав. клинико-диагностической лаб.
Russian Federation, MoscowNatalia A. Bodunova
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0002-3119-7673
канд. мед. наук, рук. центра персонализированной медицины
Russian Federation, MoscowAsfold I. Parfenov
Loginov Moscow Clinical Scientific Center
Email: oleg7@bk.ru
ORCID iD: 0000-0002-9782-4860
д-р мед. наук, проф., рук. отд. патологии кишечника
Russian Federation, MoscowReferences
- Хатьков И.Е., Парфенов А.И., Князев О.В., и др. Воспалительные заболевания кишечника в практике терапевта и хирурга. М.: Вита-ПРЕСС, 2017 [Khat'kov IE, Parfenov AI, Kniazev OV, et al. Vospalitel'nye zabolevaniia kishechnika v praktike terapevta i khirurga. Moscow: Vita-PRESS, 2017 (in Russian)].
- Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2007;102:174-86. doi: 10.1111/j.1572-0241.2006.00943.x.
- Suárez Ferrer C, Vera Mendoza MI, Amo San Román L, et al. Risk of thromboembolic phenomena in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2012;35:634-9. doi: 10.1016/j.gastrohep.2012.07.003
- Twig G, Zandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease: Mechanisms and clinical applications. Ann N Y Acad Sci. 2005;1051:166-73. doi: 10.1196/annals.1361.058
- Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000;35:619-23.
- Sloan WP Jr, Bargen JA, Gage RP. Life histories of patients with chronic ulcerative colitis: A review of 2,000 cases. Gastroenterology. 1950;16:25-38.
- Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis III complications. Gut. 1964;5:1-22.
- Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140-5.
- Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost. 2001;85:430-4.
- Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:953-62. doi: 10.1111/apt.12294
- Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657-63. doi: 10.1016/S0140-6736(09)61963-2
- Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:1001275. doi: 10.1371/journal.pmed.1001275
- Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97-101. doi: 10.1046/j.1572-0241.2003.04026
- Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:266-72. doi: 10.1038/ncpgasthep0190
- Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis – current understanding from an epidemiological point of view. Br J Haematol. 2010;149:824. doi: 10.1111/j.1365-2141.2010.08206.x
- Spina L, Saibeni S, Battaglioli T, et al. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol. 2005;100:2036-4116. doi: 10.1111/j.1572-0241.2005.42029
- Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835-48. doi: 10.1053/j.gastro.2014.01.042
- Alkim H, Koksal AR, Boga S, et al. Etiopathogenesis, Prevention, and treatment of thromboembolism in inflammatory bowel disease. Clin Appl Thromb Hemost. 2017;23(6):501-10. doi: 10.1177/1076029616632906
- Ивашкин В.Т., Шелыгин Ю.А., Белоусова Е.А., и др. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7-36 [Ivashkin VT, Shelygin YuA, Belousova EA, et al. Draft Clinical guidelines for the diagnosis and treatment of ulcerative colitis. Coloproctology. 2019;18(4):7-36 (in Russian)]. doi: 10.33878/2073-7556-2019-18-4-7-36
- Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315(8167):514.
- Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2017;4(2):44-6 [Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEO). Phlebology. 2017;4(2):44-6 (in Russian)].
- Кузнецова Б.А. Лабораторные методы исследования системы свертывания крови. Под ред. И.Н. Бокарева; РАТГПСС им. А. Шмидта. М.: Минздравсоцразвития РФ, 2011 [Kuznetsova BA. Laboratornye metody issledovaniia sistemy svertyvaniia krovi. Pod red. IN Bokareva; RATGPSS im. A. Shmidta. Moscow: Minzdravsotsrazvitiia RF, 2011 (in Russian)].
- Cтоменская И.С., Кострова О.Ю., Стручко Г.Ю., Тимофеева Н.Ю. Тромбоэластометрия – метод лабораторной диагностики нарушений системы гемостаза. Мед. альманах. 2017;2:96-8 [Stomenskaia IS, Kostrova OIu, Struchko GIu, Timofeeva NIu. Thromboelastometry is a method. I.S. Stomenskaya, et al. Medical Almanac. 2017;2:96-8 (in Russian)].
- Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J Gastroenterol. 2014;20:4857-72. doi: 10.3748/wjg.v20.i17.4857
- Algahtani FH, Farag YMK, Aljebreen AM, et al. Thromboembolic events in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2016;22(6):423-7. doi: 10.4103/1319-3767.195558
- Галстян Г.М., Полеводова О.А., Гавриш А.Ю., и др. Тромботические осложнения у больных гемофилией. Терапевтический архив. 2017;89(7):76-84 [Galstyan GM, Polevodova OA, Gavrish AYu, et al. Thrombotic complications in patients with hemophilia. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(7):76-84 (in Russian)]. doi: 10.17116/terarkh201789776-84
- Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:619-23.
- Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18:555-9.
- Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-62. doi: 10.1056/NEJM200008173430702
- Chiarantini E, Valanzano R, Liotta AA. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 1996;82:137-46.
- Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1+2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995;7:1183-8.
- Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res. 1999;19:757-60.
- Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn’s disease. Gastroenterology. 1999;117:58-64.
- Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations – United States, 2007–2009. MMWR Morb Mortal Wkly Rep. 2012;61:401-4.
- Faye AS, Hung KW, Cheng K, et al. Minor hematochezia decreases use of venous thromboembolism prophylaxis in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;26(9):1394-400. doi: 10.1093/ibd/izz269; PMID: 31689354
- Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(10):953-62. doi: 10.1111/apt.1229
- Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(9):2272-80. doi: 10.1111/j.15720241.2008.02052.x